SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Is WntResearch close to a deal with BP ?
WNT.ST 5.300-2.2%Feb 24 3:00 PM EDT

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
From: loparn9/11/2017 5:56:09 AM
   of 4
 
A new prostate cancer preclinical study is published with fine results for Foxy-5 in vitro and in mice.

"WntResearch's Chief Scientific Officer, Professor Tommy Andersson, together with his research team, and in collaboration with Professor Anders Bjartell's research group, both at Lund University, has published a scientific article in the journal PLOS ONE. The article describes how Foxy-5 inhibits spread of prostate cancer cells in a model where Foxy-5 treatment is not commenced until after a primary tumor has been established in the prostate."

www.aktietorget.se/NewsItem.aspx?ID=85468

press.aktietorget.se/Wntresearch/85468/720570.pdf
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext